Analysts have slightly lowered their price target for Labcorp Holdings from $300.12 to $299.71, citing small adjustments to profit margin and future growth expectations.
What's in the News
- Labcorp Plasma Detect, a blood-based assay for detecting molecular residual disease, was featured in peer-reviewed publications for its potential in early cancer progression tracking and improving treatment strategies for rare cancers. (Key Developments)
- Labcorp and Lunit launched a collaboration to accelerate use of digital pathology and AI in cancer research, showcasing breakthroughs in profiling non-small cell lung cancer and plans to expand AI-powered pathology to additional cancer types. (Key Developments)
- Labcorp will offer the Elecsys pTau181 blood test, recently cleared by the FDA, to support initial Alzheimer’s disease assessment in primary care. The aim is to make advanced detection more accessible nationwide. (Key Developments)
- The company updated its 2025 financial guidance to a revenue range of 7.4% to 8.0%, compared to the previous 7.5% to 8.6%. (Key Developments)
- Labcorp has repurchased 100,000 shares in the latest tranche, completing a total repurchase of 14,359,458 shares since December 2021. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has decreased slightly from $300.12 to $299.71.
- Discount Rate has edged down marginally from 6.96% to 6.96%.
- Revenue Growth projections have risen slightly from 4.78% to 4.80%.
- Net Profit Margin expectations have decreased from 8.73% to 8.55%.
- Future P/E ratio forecast has increased from 21.24x to 21.66x.
Have other thoughts on Labcorp Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.